AbbVie's Migraine Drug Cleared for Migraine Attacks on NHS

Why It Matters

The approval adds a fast‑acting, oral CGRP option to the NHS formulary, expanding treatment choices for patients who lack effective acute therapies and potentially reducing reliance on injectable drugs. It also signals strong market momentum for CGRP inhibitors in both preventive and acute migraine care.

Key Takeaways

• NICE approves Aquipta for acute migraine after two triptans fail
• Aquipta achieved 24.3% pain‑free rate at 2 hours vs 13.1% placebo
• Global sales of Qulipta/Aquipta hit $1.03 billion in 2023
• Access may vary by Integrated Care Board, risking postcode lottery
• AbbVie plans phase 3 menstrual migraine data release H2 2024

Pulse Analysis

The NHS’s decision to commission Aquipta marks a pivotal shift in migraine management within the UK’s public health system. By endorsing an oral CGRP antagonist for acute attacks, NICE expands therapeutic options beyond traditional triptans and over‑the‑counter analgesics. This move reflects growing confidence in CGRP pathway modulation, a strategy that has reshaped migraine care over the past decade. For clinicians, the guidance clarifies eligibility—patients who have tried at least two triptans or cannot tolerate them—streamlining prescribing pathways across primary and secondary care.

Clinical evidence underpins the approval. In the phase 3 ECLIPSE trial, 24.3% of Aquipta‑treated participants reported complete pain relief two hours after dosing, compared with 13.1% on placebo, demonstrating a statistically meaningful benefit. The drug’s oral formulation offers a convenient alternative to injectable CGRP therapies such as Aimovig, potentially improving adherence. Financially, Aquipta (marketed as Qulipta in the U.S.) contributed $1.03 billion to AbbVie’s 2023 revenue, positioning it as the leading oral CGRP preventive agent and rivaling Pfizer’s Nurtec ODT. The addition of an acute indication could further boost sales, reinforcing AbbVie’s dominance in the migraine market.

Looking ahead, access consistency will be critical. While the NHS endorsement removes a regulatory barrier, local Integrated Care Boards retain commissioning authority, raising concerns about a postcode‑based disparity in availability. AbbVie is also advancing the therapeutic frontier by testing Aquipta and Ubrelvy for menstrual migraine, with phase 3 results expected in the second half of 2024. Successful outcomes could trigger European filings before year‑end and a U.S. submission in early 2027, expanding the drug’s footprint and offering a much‑needed solution for a subset of women who experience severe, hormone‑linked attacks.